Properties of Protein Drug Target Classes
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Accurate identification of drug targets is a crucial part of any drug development program. We mined the human proteome to discover properties of proteins that may be important in determining their suitability for pharmaceutical modulation. Data was gathered concerning each protein's sequence, post-translational modifications, secondary structure, germline variants, expression profile and drug target status. The data was then analysed to determine features for which the target and non-target proteins had significantly different values. This analysis was repeated for subsets of the proteome consisting of all G-protein coupled receptors, ion channels, kinases and proteases, as well as proteins that are implicated in cancer. Machine learning was used to quantify the proteins in each dataset in terms of their potential to serve as a drug target. This was accomplished by first inducing a random forest that could distinguish between its targets and non-targets, and then using the random forest to quantify the drug target likeness of the non-targets. The properties that can best differentiate targets from non-targets were primarily those that are directly related to a protein's sequence (e.g. secondary structure). Germline variants, expression levels and interactions between proteins had minimal discriminative power. Overall, the best indicators of drug target likeness were found to be the proteins' hydrophobicities, in vivo half-lives, propensity for being membrane bound and the fraction of non-polar amino acids in their sequences. In terms of predicting potential targets, datasets of proteases, ion channels and cancer proteins were able to induce random forests that were highly capable of distinguishing between targets and non-targets. The non-target proteins predicted to be targets by these random forests comprise the set of the most suitable potential future drug targets, and should therefore be prioritised when building a drug development programme.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
BLAST+: architecture and applications
Camacho, C., Coulouris, G., Avagyan, V., Ma, N., Papadopoulos, J., Bealer, K., & Madden, T. L. (2009) · BMC Bioinformatics · doi:10.1186/1471-2105-10-421 · Cited by 22,074
How many drug targets are there?
Overington, J. P., Al-Lazikani, B., & Hopkins, A. L. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2199 · Cited by 3,505
Hopkins, A. L., & Groom, C. R. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd892 · Cited by 3,305 · cited 4×
“The vast majority of the targets of approved drugs are proteins [1,2].”
BackgroundInfluentialA census of human cancer genes
Futreal, P. A., Coin, L., Marshall, M., Down, T., Hubbard, T., Wooster, R., Rahman, N., & Stratton, M. R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1299 · Cited by 3,184 · cited 2×
“The CGC dataset (accessed on June 15th 2012) was parsed in order to determine the NCBI Gene IDs of genes that are causally implicated in cancer.”
MethodFredriksson, R., Lagerström, M. C., Lundin, L.-G., & Schiöth, H. B. (2003) · Molecular Pharmacology · doi:10.1124/mol.63.6.1256 · Cited by 2,941 · cited 1×
“that there are approximately 800 GPCRs coded for by the human genome [11], and the knowledge that there are just over 20,000 human proteins [12], we can estimate that roughly 4% of human proteins are GPCRs.”
BackgroundAngiogenesis as a therapeutic target
Ferrara, N., & Kerbel, R. S. (2005) · Nature · doi:10.1038/nature04483 · Cited by 2,653 · cited 1×
“blood supply can be cut off by preventing angiogenesis, as done by the drug Bevacizumab’s inhibition of vascular endothelial growth factor A [16].”
BackgroundRoles of N-Linked Glycans in the Endoplasmic Reticulum
Helenius, A., & Aebi, M. (2004) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.73.011303.073752 · Cited by 2,037 · cited 1×
“As N-linked glycosylation has been associated with increased protein stability and protection against degradation and denaturation, in addition to ensuring the correct folding of proteins [50,51], the greater number of N-linked glycosylation sites likely indicates that positive proteins have a greater half-life in viv…”
BackgroundA common language effect size statistic
McGraw, K. O., & Wong, S. P. (1992) · Psychological Bulletin · doi:10.1037/0033-2909.111.2.361 · Cited by 934 · cited 1×
“The effect size was calculated by estimating the probability of superiority (PS), also known as the common language effect size [49], defined by PS = U/m n, where U is the U statistic of the positive observations from the MannWhitney U test,m the number of positive observations in the dataset and n the number of unlab…”
MethodTrends in the exploitation of novel drug targets
Rask-Andersen, M., Almén, M. S., & Schiöth, H. B. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3478 · Cited by 853 · cited 2×
“found that G-protein-coupled receptors (GPCRs) make up 44% of human drug targets, enzymes 29% and transporter proteins 15% [7]; Overington et al.”
BackgroundTelomerase and cancer therapeutics
Harley, C. B. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2275 · Cited by 728 · cited 1×
“For example, the immortalisation of cancer cells could be attacked via the targeting of telomerase, as it is both specific to cancerous cells and necessary for their survival [15]; molecular alterations that deregulate growth can be corrected, as with Imatinib’s targeting of the BCR-ABL protein in chronic myelogenous…”
Background
Cited by
Deep learning methods for protein function prediction
Boadu, F., Lee, A., & Cheng, J. (2025) · PROTEOMICS · doi:10.1002/pmic.202300471 · Cited by 53
“One or multiple sources of data such as protein sequences, protein structures (e.g., structures retrieved from the AlphaFoldDB [17] and the Protein Data Bank [PDB] [18]), protein–protein interaction from the STRING database [19], protein family and domain information from the Interpro database [20], and the textual de…”
Identifying therapeutic targets for cancer among 2074 circulating proteins and risk of nine cancers
Smith-Byrne, K., Hedman, Å., Dimitriou, M., Desai, T., Sokolov, A. V., Schioth, H. B., Koprulu, M., Pietzner, M., Langenberg, C., Atkins, J., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46834-3 · Cited by 33
“Proteins are essential targets for drug development 30 .”
BackgroundCunningham, M., Pins, D., Dezső, Z., Torrent, M., Vasanthakumar, A., & Pandey, A. (2023) · Journal of Cheminformatics · doi:10.1186/s13321-023-00735-7 · Cited by 13
Metadata
- Authors
- Bull, S. C., & Doig, A. J.
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2015-03-30
- Volume
- 10
- Issue
- 3
- Pages
- e0117955
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2081837827
- Cited by
- 135
- References
- 11
- FWCI
- 10.98
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Properties of Protein Drug Target Classes. https://app.cochat.ai/papers/10.1371/journal.pone.0117955
- The paper
- Bull, S. C., & Doig, A. J. (2015). Properties of Protein Drug Target Classes. PLOS ONE. https://doi.org/10.1371/journal.pone.0117955
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.